Capital Royalty To Offer Debt With New $1 Billion Fund
This article was originally published in The Pink Sheet Daily
As the royalty field grows more crowded, the health care investor is turning away from passive royalties, the core strategy of its first fund, to become a lender to companies with products on the market or already approved.
You may also be interested in...
Toronto-based health care royalty acquirer raises a $1.45 billion third fund, which it says should last between three-and-a-half and five years. It is mainly sticking with its prior investment strategy, although for the first time DRI will look at acquiring royalty rights to promising Phase III candidates.
Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.
TearScience Inc. is ready to go into full-scale commercialization for a new device treatment for the most prevalent form of dry eye. In late February, the young company secured up to $70 million from HealthCare Royalty Partners to help make that happen.